Cargando…

Therapeutic Potential of Ginsenosides as an Adjuvant Treatment for Diabetes

Ginseng, one of the oldest traditional Chinese medicinal herbs, has been used widely in China and Asia for thousands of years. Ginsenosides extracted from ginseng, which is derived from the roots and rhizomes of Panax ginseng C. A. Meyer, have been used in China as an adjuvant in the treatment of di...

Descripción completa

Detalles Bibliográficos
Autores principales: Bai, Litao, Gao, Jialiang, Wei, Fan, Zhao, Jing, Wang, Danwei, Wei, Junping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5938666/
https://www.ncbi.nlm.nih.gov/pubmed/29765322
http://dx.doi.org/10.3389/fphar.2018.00423
_version_ 1783320824771510272
author Bai, Litao
Gao, Jialiang
Wei, Fan
Zhao, Jing
Wang, Danwei
Wei, Junping
author_facet Bai, Litao
Gao, Jialiang
Wei, Fan
Zhao, Jing
Wang, Danwei
Wei, Junping
author_sort Bai, Litao
collection PubMed
description Ginseng, one of the oldest traditional Chinese medicinal herbs, has been used widely in China and Asia for thousands of years. Ginsenosides extracted from ginseng, which is derived from the roots and rhizomes of Panax ginseng C. A. Meyer, have been used in China as an adjuvant in the treatment of diabetes mellitus. Owing to the technical complexity of ginsenoside production, the total ginsenosides are generally extracted. Accumulating evidence has shown that ginsenosides exert antidiabetic effects. In vivo and in vitro tests revealed the potential of ginsenoside Rg1, Rg3, Rg5, Rb1, Rb2, Rb3, compound K, Rk1, Re, ginseng total saponins, malonyl ginsenosides, Rd, Rh2, F2, protopanaxadiol (PPD) and protopanaxatriol (PPT)-type saponins to treat diabetes and its complications, including type 1 diabetes mellitus, type 2 diabetes mellitus, diabetic nephropathy, diabetic cognitive dysfunction, type 2 diabetes mellitus with fatty liver disease, diabetic cerebral infarction, diabetic cardiomyopathy, and diabetic erectile dysfunction. Many effects are attributed to ginsenosides, including gluconeogenesis reduction, improvement of insulin resistance, glucose transport, insulinotropic action, islet cell protection, hepatoprotective activity, anti-inflammatory effect, myocardial protection, lipid regulation, improvement of glucose tolerance, antioxidation, improvement of erectile dysfunction, regulation of gut flora metabolism, neuroprotection, anti-angiopathy, anti-neurotoxic effects, immunosuppression, and renoprotection effect. The molecular targets of these effects mainly contains GLUTs, SGLT1, GLP-1, FoxO1, TNF-α, IL-6, caspase-3, bcl-2, MDA, SOD, STAT5-PPAR gamma pathway, PI3K/Akt pathway, AMPK-JNK pathway, NF-κB pathway, and endoplasmic reticulum stress. Rg1, Rg3, Rb1, and compound K demonstrated the most promising therapeutic prospects as potential adjuvant medicines for the treatment of diabetes. This paper highlights the underlying pharmacological mechanisms of the anti-diabetic effects of ginsenosides.
format Online
Article
Text
id pubmed-5938666
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-59386662018-05-14 Therapeutic Potential of Ginsenosides as an Adjuvant Treatment for Diabetes Bai, Litao Gao, Jialiang Wei, Fan Zhao, Jing Wang, Danwei Wei, Junping Front Pharmacol Pharmacology Ginseng, one of the oldest traditional Chinese medicinal herbs, has been used widely in China and Asia for thousands of years. Ginsenosides extracted from ginseng, which is derived from the roots and rhizomes of Panax ginseng C. A. Meyer, have been used in China as an adjuvant in the treatment of diabetes mellitus. Owing to the technical complexity of ginsenoside production, the total ginsenosides are generally extracted. Accumulating evidence has shown that ginsenosides exert antidiabetic effects. In vivo and in vitro tests revealed the potential of ginsenoside Rg1, Rg3, Rg5, Rb1, Rb2, Rb3, compound K, Rk1, Re, ginseng total saponins, malonyl ginsenosides, Rd, Rh2, F2, protopanaxadiol (PPD) and protopanaxatriol (PPT)-type saponins to treat diabetes and its complications, including type 1 diabetes mellitus, type 2 diabetes mellitus, diabetic nephropathy, diabetic cognitive dysfunction, type 2 diabetes mellitus with fatty liver disease, diabetic cerebral infarction, diabetic cardiomyopathy, and diabetic erectile dysfunction. Many effects are attributed to ginsenosides, including gluconeogenesis reduction, improvement of insulin resistance, glucose transport, insulinotropic action, islet cell protection, hepatoprotective activity, anti-inflammatory effect, myocardial protection, lipid regulation, improvement of glucose tolerance, antioxidation, improvement of erectile dysfunction, regulation of gut flora metabolism, neuroprotection, anti-angiopathy, anti-neurotoxic effects, immunosuppression, and renoprotection effect. The molecular targets of these effects mainly contains GLUTs, SGLT1, GLP-1, FoxO1, TNF-α, IL-6, caspase-3, bcl-2, MDA, SOD, STAT5-PPAR gamma pathway, PI3K/Akt pathway, AMPK-JNK pathway, NF-κB pathway, and endoplasmic reticulum stress. Rg1, Rg3, Rb1, and compound K demonstrated the most promising therapeutic prospects as potential adjuvant medicines for the treatment of diabetes. This paper highlights the underlying pharmacological mechanisms of the anti-diabetic effects of ginsenosides. Frontiers Media S.A. 2018-05-01 /pmc/articles/PMC5938666/ /pubmed/29765322 http://dx.doi.org/10.3389/fphar.2018.00423 Text en Copyright © 2018 Bai, Gao, Wei, Zhao, Wang and Wei. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Bai, Litao
Gao, Jialiang
Wei, Fan
Zhao, Jing
Wang, Danwei
Wei, Junping
Therapeutic Potential of Ginsenosides as an Adjuvant Treatment for Diabetes
title Therapeutic Potential of Ginsenosides as an Adjuvant Treatment for Diabetes
title_full Therapeutic Potential of Ginsenosides as an Adjuvant Treatment for Diabetes
title_fullStr Therapeutic Potential of Ginsenosides as an Adjuvant Treatment for Diabetes
title_full_unstemmed Therapeutic Potential of Ginsenosides as an Adjuvant Treatment for Diabetes
title_short Therapeutic Potential of Ginsenosides as an Adjuvant Treatment for Diabetes
title_sort therapeutic potential of ginsenosides as an adjuvant treatment for diabetes
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5938666/
https://www.ncbi.nlm.nih.gov/pubmed/29765322
http://dx.doi.org/10.3389/fphar.2018.00423
work_keys_str_mv AT bailitao therapeuticpotentialofginsenosidesasanadjuvanttreatmentfordiabetes
AT gaojialiang therapeuticpotentialofginsenosidesasanadjuvanttreatmentfordiabetes
AT weifan therapeuticpotentialofginsenosidesasanadjuvanttreatmentfordiabetes
AT zhaojing therapeuticpotentialofginsenosidesasanadjuvanttreatmentfordiabetes
AT wangdanwei therapeuticpotentialofginsenosidesasanadjuvanttreatmentfordiabetes
AT weijunping therapeuticpotentialofginsenosidesasanadjuvanttreatmentfordiabetes